ReviewCurrent rheumatology reports2017
Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment.
Review in Current rheumatology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Characteristics and factors associated with treatment response among patients with eosinophilic fasciitis: a systematic review and meta-analysis.Rheumatology international · 2025Pooled it
- Eosinophilic Fasciitis With Overlap Connective Tissue Disease: A Diagnostic Challenge in Progressive Skin Fibrosis.Cureus · 2026Article
- [A typical myofascial pain syndrome, or perhaps not? : Rare differential diagnosis].Innere Medizin (Heidelberg, Germany) · 2026Article
- The utility of rituximab in patients with eosinophilic fasciitis: case series from an Australian tertiary multidisciplinary clinic.Clinical rheumatology · 2026Article
- Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation.Frontiers in oncology · 2026Article
- Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.The American journal of case reports · 2025Article
- Eosinophilic Fasciitis after Covid Infection: A Case Report and Review of Literature.Clinical medicine & research · 2025Review
- Clinicopathological profile of eosinophilic fasciitis: a retrospective cohort study from a neuromuscular disorder center in China.Arthritis research & therapy · 2025Article
- Unilateral Eosinophilic Fasciitis With Hand Involvement: A Case Report.Clinical case reports · 2025Article
- Imaging mimickers of MSK infection.Skeletal radiology · 2024Review
- Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis.Science translational medicine · 2024Review
- The use of dupilumab in treatment-refractory eosinophilic fasciitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Article
- Article
- [Imaging of eosinophilic fasciitis in ultrasound and MRI (magnetic resonance imaging): a case report].Zeitschrift fur Rheumatologie · 2024Article
- [Localized scleroderma].Dermatologie (Heidelberg, Germany) · 2024Review
- Juvenile eosinophilic fasciitis: a single center case series.Pediatric rheumatology online journal · 2024Article
- Scleroderma and scleroderma-like syndromes.Frontiers in immunology · 2024Review
- Diagnostic imaging for eosinophilic fasciitis: A systematic review.JAAD international · 2023Article
- Diffuse fasciitis with eosinophilia in boys: a case-based review.Rheumatology international · 2023Review
- Eosinophilic fasciitis following SARS-CoV-2 vaccination.JAAD case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewFirst recognized in 1974, eosinophilic fasciitis (EF) is a fibrosing disorder of the fascia with characteristic cutaneous and hematologic manifestations. This review discusses recent trends in the diagnosis and treatment of EF. RECENT
findingsAlthough fascial biopsy has classically been considered the gold standard for making a diagnosis of EF, radiologic imaging, particularly magnetic resonance imaging, has been increasingly used for both diagnosis and monitoring of treatment response. Systemic corticosteroids remain the first-line treatment for EF; however, their often prolonged use in the treatment of EF has prompted a search for adjunctive therapies. Methotrexate has emerged as the leading corticosteroid-sparing agent for EF. Since EF was initially described over 40 years ago, important diagnostic and therapeutic progress has been made. Future efforts should be directed at the pursuit of prospective studies including clinical trials and evidence-based guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.